Skip to main content
OpenTrials
Completed

NCT Number: NCT02146807

Laser Treatment of Tattoos With Pico Laser

The purpose of this study is to determine whether Pico laser is effective and safe in the treatment of unwanted tattoos.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Washington Institute of Dermatologic Laser Surgery, Washington D.C., District of Columbia, United States

Loading trial locations.

About this study

The Investigational device is a dual wavelength laser system developed for treatment of pigmented lesions and for tattoo removal. The base unit is a GentleMax Pro laser system modified to emit light at wavelengths of 532 and 1064 nm and deliver pulse energy up to 400mJ, and pulse duration of 700 ps.

A multicenter study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has Fitzpatrick skin type I-IV
  • Has unwanted non-cosmetic tattoo(s) and wishes to undergo laser treatments to remove them
  • Is willing to consent to participate in the study
  • Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits

Exclusion criteria

  • Is hypersensitive to light exposure
  • Has an active sun tan
  • Has Fitzpatrick skin type V or VI
  • Has active localized or systemic infection
  • Is taking medication(s) for which sunlight is a contraindication
  • Has a history of squamous cell carcinoma or melanoma
  • Has a history of keloid scarring
  • Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment.
  • Has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications
  • Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period
  • Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine

Treatment and study plan

Picosecond Laser system

Device

Picosecond Laser System for the Treatment of Unwanted Tattoos

Primary outcomes

  1. Global percentage of tattoo clearance

    Time frame: 3 months post the final treatment

    Global percentage of tattoo clearance evaluated by blinded observers using post treatment photographs compared to baseline photographs.

Secondary outcomes

  1. Rate of tattoo clearance

    Time frame: 3 months

    The average number of treatments will be determined in order to obtain 50% and 75% tattoo clearance. Rate of clearance will be assessed globally independent of tattoo color and based on individual colors.

Other outcomes

  1. Number of Participants with Adverse Events

    Time frame: 3 months

    Adverse events will be evaluated immediately after and before each subsequent laser treatment and will be based on the incidence and severity of side effects caused by the laser treatments.

Sponsors and collaborators

Lead sponsor

Syneron Medical

Industry

Registry information

Official study title

LASER TREATMENT OF TATTOOS WITH A DUAL WAVELENGTH PICOSECOND LASER

Important dates

Study start
2013
Primary completion
2015
First posted
May 26, 2014
Registry last updated
Jun 26, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.